{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:27:06Z","timestamp":1768476426914,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Microsomal prostaglandin E2 synthase-1 (mPGES-1) is known as an ideal target for next generation of anti-inflammatory drugs without the side effects of currently available anti-inflammatory drugs. However, there has been no clinically promising mPGES-1 inhibitor identified through traditional drug discovery and development route. Here we report a new approach, called DREAM-<jats:italic>in<\/jats:italic>-CDM (<jats:underline>D<\/jats:underline>rug<jats:underline>R<\/jats:underline>epurposing<jats:underline>E<\/jats:underline>ffort<jats:underline>A<\/jats:underline>pplying Integrated<jats:underline>M<\/jats:underline>odeling-<jats:italic><jats:underline>in<\/jats:underline><\/jats:italic><jats:italic>vitro\/vivo<\/jats:italic>-<jats:underline>C<\/jats:underline>linical<jats:underline>D<\/jats:underline>ata<jats:underline>M<\/jats:underline>ining), to identify an FDA-approved drug suitable for use as an effective analgesic targeting mPGES-1. The DREAM-<jats:italic>in<\/jats:italic>-CDM approach consists of three steps: computational screening of FDA-approved drugs;<jats:italic>in vitro<\/jats:italic>and\/or<jats:italic>in vivo<\/jats:italic>assays; and clinical data mining. By using the DREAM-<jats:italic>in<\/jats:italic>-CDM approach, lapatinib has been identified as a promising mPGES-1 inhibitor which may have significant anti-inflammatory effects to relieve various forms of pain and possibly treat various inflammation conditions involved in other inflammation-related diseases such as the lung inflammation caused by the newly identified COVID-19. We anticipate that the DREAM-<jats:italic>in<\/jats:italic>-CDM approach will be used to repurpose FDA-approved drugs for various new therapeutic indications associated with new targets.<\/jats:p>","DOI":"10.1038\/s41598-020-67283-0","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T10:02:51Z","timestamp":1592906571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1"],"prefix":"10.1038","volume":"10","author":[{"given":"Shuo","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxia","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Loftin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Guo","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"67283_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2796.2010.02246.x","volume":"268","author":"O Radmark","year":"2010","unstructured":"Radmark, O. & Samuelsson, B. Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer. J. Intern. Med. 268, 5\u201314 (2010).","journal-title":"J. Intern. Med."},{"key":"67283_CR2","doi-asserted-by":"publisher","first-page":"18757","DOI":"10.1073\/pnas.0910218106","volume":"106","author":"H Hanaka","year":"2009","unstructured":"Hanaka, H. et al. Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc. Natl. Acad. Sci. USA 106, 18757\u201318762 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67283_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.06.022","volume":"98","author":"A Koeberle","year":"2015","unstructured":"Koeberle, A. & Werz, O. Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders. Biochem. Pharmacol. 98, 1\u201315 (2015).","journal-title":"Biochem. Pharmacol."},{"key":"67283_CR4","doi-asserted-by":"publisher","first-page":"8609","DOI":"10.1073\/pnas.1733589100","volume":"100","author":"CN Serhan","year":"2003","unstructured":"Serhan, C. N. & Levy, B. Success of prostaglandin E-2 in structure-function is a challenge for structure-based therapeutics. Proc. Natl. Acad. Sci. USA 100, 8609\u20138611, https:\/\/doi.org\/10.1073\/pnas.1733589100 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67283_CR5","first-page":"633","volume":"38","author":"I Kudo","year":"2005","unstructured":"Kudo, I. & Murakami, M. Prostaglandin E synthase, a terminal enzyme for prostaglandin E-2 biosynthesis. J. Biochem. Mol. Biol. 38, 633\u2013638 (2005).","journal-title":"J. Biochem. Mol. Biol."},{"key":"67283_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/01.bor.0000129664.81052.8e","volume":"16","author":"H Fahmi","year":"2004","unstructured":"Fahmi, H. MPGES-1 as a novel target for arthritis. Curr. Opin. Rheumatol. 16, 623\u2013627 (2004).","journal-title":"Curr. Opin. Rheumatol."},{"key":"67283_CR7","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1172\/jci27540","volume":"116","author":"Y Cheng","year":"2006","unstructured":"Cheng, Y. et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest. 116, 1391\u20131399, https:\/\/doi.org\/10.1172\/jci27540 (2006).","journal-title":"J. Clin. Invest."},{"key":"67283_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/nn1137","volume":"6","author":"D Engblom","year":"2003","unstructured":"Engblom, D. et al. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nature Neurosci. 6, 1137\u20131138, https:\/\/doi.org\/10.1038\/nn1137 (2003).","journal-title":"Nature Neurosci."},{"key":"67283_CR9","doi-asserted-by":"publisher","first-page":"9044","DOI":"10.1073\/pnas.1332766100","volume":"100","author":"CE Trebino","year":"2003","unstructured":"Trebino, C. E. et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl. Acad. Sci. USA 100, 9044\u20139049, https:\/\/doi.org\/10.1073\/pnas.1332766100 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67283_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1021\/acs.jmedchem.5b01249","volume":"59","author":"MA Schiffler","year":"2016","unstructured":"Schiffler, M. A. et al. Discovery and Characterization of 2-Acylaminoimidazole Microsomal Prostaglandin E Synthase-1 Inhibitors. J. Med. Chem. 59, 194\u2013205, https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01249 (2016).","journal-title":"J. Med. Chem."},{"key":"67283_CR11","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1021\/jm200092b","volume":"54","author":"M Hieke","year":"2011","unstructured":"Hieke, M. et al. Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1\/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid. J. Med. Chem. 54, 4490\u20134507, https:\/\/doi.org\/10.1021\/jm200092b (2011).","journal-title":"J. Med. Chem."},{"key":"67283_CR12","doi-asserted-by":"publisher","first-page":"9031","DOI":"10.1021\/jm401557w","volume":"56","author":"T Hanke","year":"2013","unstructured":"Hanke, T. et al. Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo. J. Med. Chem. 56, 9031\u20139044, https:\/\/doi.org\/10.1021\/jm401557w (2013).","journal-title":"J. Med. Chem."},{"key":"67283_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1021\/ml500433j","volume":"6","author":"S Terracciano","year":"2015","unstructured":"Terracciano, S. et al. Structural Insights for the Optimization of Dihydropyrimidin-2(1H)-one Based mPGES-1 Inhibitors. ACS Med. Chem. Lett. 6, 187\u2013191, https:\/\/doi.org\/10.1021\/ml500433j (2015).","journal-title":"ACS Med. Chem. Lett."},{"key":"67283_CR14","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1016\/j.bmc.2013.03.069","volume":"21","author":"T Shiro","year":"2013","unstructured":"Shiro, T., Kakiguchi, K., Takahashi, H., Nagata, H. & Tobe, M. 7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors. Bioorg. Med. Chem. 21, 2868\u20132878, https:\/\/doi.org\/10.1016\/j.bmc.2013.03.069 (2013).","journal-title":"Bioorg. Med. Chem."},{"key":"67283_CR15","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.bmc.2013.01.018","volume":"21","author":"T Shiro","year":"2013","unstructured":"Shiro, T., Kakiguchi, K., Takahashi, H., Nagata, H. & Tobe, M. Synthesis and biological evaluation of substituted imidazoquinoline derivatives as mPGES-1 inhibitors. Bioorg. Med. Chem. 21, 2068\u20132078, https:\/\/doi.org\/10.1016\/j.bmc.2013.01.018 (2013).","journal-title":"Bioorg. Med. Chem."},{"key":"67283_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bmcl.2011.11.015","volume":"22","author":"T Shiro","year":"2012","unstructured":"Shiro, T. et al. Synthesis and SAR study of imidazoquinolines as a novel structural class of microsomal prostaglandin E(2) synthase-1 inhibitors. Bioorg. Med. Chem. Lett. 22, 285\u2013288, https:\/\/doi.org\/10.1016\/j.bmcl.2011.11.015 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"67283_CR17","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1021\/jm900481c","volume":"52","author":"AJ Liedtke","year":"2009","unstructured":"Liedtke, A. J. et al. Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). J. Med. Chem. 52, 4968\u20134972, https:\/\/doi.org\/10.1021\/jm900481c (2009).","journal-title":"J. Med. Chem."},{"key":"67283_CR18","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1016\/j.bmcl.2014.04.006","volume":"24","author":"E Shang","year":"2014","unstructured":"Shang, E. et al. Benzo[d]isothiazole 1,1-dioxide derivatives as dual functional inhibitors of 5-lipoxygenase and microsomal prostaglandin E(2) synthase-1. Bioorg. Med. Chem. Lett. 24, 2764\u20132767, https:\/\/doi.org\/10.1016\/j.bmcl.2014.04.006 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"67283_CR19","doi-asserted-by":"publisher","first-page":"6978","DOI":"10.1016\/j.bmcl.2010.09.129","volume":"20","author":"TY Wu","year":"2010","unstructured":"Wu, T. Y. et al. Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1. Bioorg. Med. Chem. Lett. 20, 6978\u20136982, https:\/\/doi.org\/10.1016\/j.bmcl.2010.09.129 (2010).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"67283_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejmech.2011.12.009","volume":"48","author":"A Wiegard","year":"2012","unstructured":"Wiegard, A., Hanekamp, W., Griessbach, K., Fabian, J. & Lehr, M. Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1. Eur. J. Med. Chem. 48, 153\u2013163, https:\/\/doi.org\/10.1016\/j.ejmech.2011.12.009 (2012).","journal-title":"J. Med. Chem."},{"key":"67283_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ejmech.2012.05.014","volume":"54","author":"MG Chini","year":"2012","unstructured":"Chini, M. G. et al. Design and synthesis of a second series of triazole-based compounds as potent dual mPGES-1 and 5-lipoxygenase inhibitors. Eur. J. Med. Chem. 54, 311\u2013323, https:\/\/doi.org\/10.1016\/j.ejmech.2012.05.014 (2012).","journal-title":"Eur. J. Med. Chem."},{"key":"67283_CR22","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.1016\/j.bmcl.2009.08.085","volume":"19","author":"A Giroux","year":"2009","unstructured":"Giroux, A. et al. Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors. Bioorg. Med. Chem. Lett. 19, 5837\u20135841, https:\/\/doi.org\/10.1016\/j.bmcl.2009.08.085 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"67283_CR23","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1124\/jpet.108.138776","volume":"326","author":"D Xu","year":"2008","unstructured":"Xu, D. et al. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J. Pharmacol. Exp. Ther. 326, 754\u2013763, https:\/\/doi.org\/10.1124\/jpet.108.138776 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"67283_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bmcl.2012.11.019","volume":"23","author":"K Lee","year":"2013","unstructured":"Lee, K. et al. Fragment-based discovery of novel and selective mPGES-1 inhibitors Part 1: identification of sulfonamido-1,2,3-triazole-4,5-dicarboxylic acid. Bioorg. Med. Chem. Lett. 23, 75\u201380, https:\/\/doi.org\/10.1016\/j.bmcl.2012.11.019 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"67283_CR25","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1016\/j.bmcl.2007.10.033","volume":"17","author":"B Cote","year":"2007","unstructured":"Cote, B. et al. Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg. Med. Chem. Lett. 17, 6816\u20136820, https:\/\/doi.org\/10.1016\/j.bmcl.2007.10.033 (2007).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"67283_CR26","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1016\/j.bmcl.2005.05.027","volume":"15","author":"D Riendeau","year":"2005","unstructured":"Riendeau, D. et al. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg. Med. Chem. Lett. 15, 3352\u20133355, https:\/\/doi.org\/10.1016\/j.bmcl.2005.05.027 (2005).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"67283_CR27","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.bcp.2009.11.011","volume":"79","author":"A Bruno","year":"2010","unstructured":"Bruno, A. et al. Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. Biochem. Pharmacol. 79, 974\u2013981, https:\/\/doi.org\/10.1016\/j.bcp.2009.11.011 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"67283_CR28","doi-asserted-by":"publisher","first-page":"7924","DOI":"10.1016\/j.bmc.2009.10.025","volume":"17","author":"A Koeberle","year":"2009","unstructured":"Koeberle, A. et al. Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1. Bioorg. Med. Chem. 17, 7924\u20137932, https:\/\/doi.org\/10.1016\/j.bmc.2009.10.025 (2009).","journal-title":"Bioorg. Med. Chem."},{"key":"67283_CR29","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.bmcl.2012.11.107","volume":"23","author":"DP Walker","year":"2013","unstructured":"Walker, D. P. et al. Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: use of a conformation-based hypothesis to facilitate compound design. Bioorg. Med. Chem. Lett. 23, 1120\u20131126, https:\/\/doi.org\/10.1016\/j.bmcl.2012.11.107 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"67283_CR30","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.bmcl.2010.01.060","volume":"20","author":"J Wang","year":"2010","unstructured":"Wang, J. et al. Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template. Bioorg. Med. Chem. Lett. 20, 1604\u20131609, https:\/\/doi.org\/10.1016\/j.bmcl.2010.01.060 (2010).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"67283_CR31","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/cpt.260","volume":"99","author":"Y Jin","year":"2016","unstructured":"Jin, Y. et al. Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib. Clin. Pharmacol. Therap. 99, 274\u2013284, https:\/\/doi.org\/10.1002\/cpt.260 (2016).","journal-title":"Clin. Pharmacol. Therap."},{"key":"67283_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-41018-23482-41594","volume":"8","author":"K Ding","year":"2018","unstructured":"Ding, K. et al. Structure-based discovery of mPGES-1 inhibitors suitable for preclinical testing in wild-type mice as a new generation of anti-inflammatory drugs. Sci. Rep. 8, 5205, https:\/\/doi.org\/10.1038\/s41598-41018-23482-41594 (2018).","journal-title":"Sci. Rep."},{"key":"67283_CR33","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1016\/j.bmcl.2017.06.075","volume":"27","author":"Z Zhou","year":"2017","unstructured":"Zhou, Z. et al. Selective inhibitors of human mPGES-1 from structure-based computational screening. Biorg. Med. Chem. Lett. 27, 3739\u20133743 (2017).","journal-title":"Biorg. Med. Chem. Lett."},{"key":"67283_CR34","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.bmcl.2018.02.011","volume":"28","author":"K Ding","year":"2018","unstructured":"Ding, K. et al. Design, synthesis, and discovery of 5-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-triones and related derivatives as novel inhibitors of mPGES-1. Bioorg. Med. Chem. Lett. 28, 858\u2013862 (2018).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"67283_CR35","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1021\/acs.jcim.9b00289","volume":"59","author":"S Zhou","year":"2019","unstructured":"Zhou, S. et al. In Silico Observation of the Conformational Opening of the Glutathione-binding Site of Microsomal Prostaglandin E2 Synthase-1. J. Chem. Inf. Model. 59, 3839\u20133845 (2019).","journal-title":"J. Chem. Inf. Model."},{"key":"67283_CR36","unstructured":"Mathieu, M. Enzo Compounds - Knowledge Base: Compound Purity, http:\/\/kb.enzolifesciences.com\/article\/what-is-the-purity-of-the-compounds-included-in-your-screen-well-natural-product-library-bml-2865-611.html (2017)."},{"key":"67283_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27\u201331 (2016).","journal-title":"J. Basic Clin. Pharm."},{"key":"67283_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1023\/B:DRUG.0000047104.45929.ea","volume":"23","author":"AK Bence","year":"2005","unstructured":"Bence, A. K. et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest. New Drugs 23, 39\u201349, https:\/\/doi.org\/10.1023\/B:DRUG.0000047104.45929.ea (2005).","journal-title":"Invest. New Drugs"},{"key":"67283_CR39","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1200\/JCO.2013.52.1161","volume":"32","author":"AJ Chien","year":"2014","unstructured":"Chien, A. J. et al. Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2\u2013Overexpressing Breast Cancer. J. Clin. Oncol. 32, 1472\u20131479 (2014).","journal-title":"J. Clin. Oncol."},{"key":"67283_CR40","doi-asserted-by":"publisher","first-page":"16579","DOI":"10.1074\/jbc.M412075200","volume":"280","author":"CE Trebino","year":"2005","unstructured":"Trebino, C. E. et al. Redirection of Eicosanoid Metabolism in mPGES-1-deficient Macrophages. J. Biol. Chem. 280, 16579\u201316585 (2005).","journal-title":"J. Biol. Chem."},{"key":"67283_CR41","doi-asserted-by":"publisher","first-page":"33684","DOI":"10.1074\/jbc.M400199200","volume":"279","author":"D Kamei","year":"2004","unstructured":"Kamei, D. et al. Reduced Pain Hypersensitivity and Inflammation in Mice Lacking Microsomal Prostaglandin E synthase-1. J. Biol. Chem. 279, 33684\u201333695 (2004).","journal-title":"J. Biol. Chem."},{"key":"67283_CR42","doi-asserted-by":"publisher","first-page":"23229","DOI":"10.1074\/jbc.M400443200","volume":"279","author":"L Boulet","year":"2004","unstructured":"Boulet, L. et al. Deletion of Microsomal Prostaglandin E2 (PGE2) synthase-1 Reduces Inducible and Basal PGE2 Production and Alters the Gastric Prostanoid Profile. J. Biol. Chem. 279, 23229\u201323237 (2004).","journal-title":"J. Biol. Chem."},{"key":"67283_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"NM O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle, N. M. et al. Open Babel: An open chemical toolbox. J. Cheminformatics 3, 33 (2011).","journal-title":"J. Cheminformatics"},{"key":"67283_CR44","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461, https:\/\/doi.org\/10.1002\/jcc.21334 (2010).","journal-title":"J. Comput. Chem."},{"key":"67283_CR45","unstructured":"Case, D. A. et al. AMBER 12, University of California, San Francisco. (2012)."},{"key":"67283_CR46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/0021-9991(83)90014-1","volume":"52","author":"HC Andersen","year":"1983","unstructured":"Andersen, H. C. Rattle: A \u201cvelocity\u201d version of the shake algorithm for molecular dynamics calculations. J. Comput. Phys. 52, 24\u201334 (1983).","journal-title":"J. Comput. Phys."},{"key":"67283_CR47","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BR Miller 3rd","year":"2012","unstructured":"Miller, B. R. 3rd et al. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. J. Chem. Theo. Comput. 8, 3314\u20133321, https:\/\/doi.org\/10.1021\/ct300418h (2012).","journal-title":"J. Chem. Theo. Comput."},{"key":"67283_CR48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1747-0285.2009.00780.x","volume":"73","author":"G Rastelli","year":"2009","unstructured":"Rastelli, G., Degliesposti, G., Del Rio, A. & Sgobba, M. Binding estimation after refinement, a new automated procedure for the refinement and rescoring of docked ligands in virtual screening. Chem. Biol. Drug Design 73, 283\u2013286 (2009).","journal-title":"Chem. Biol. Drug Design"},{"key":"67283_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/1087057110388276","volume":"16","author":"G Degliesposti","year":"2011","unstructured":"Degliesposti, G., Portioli, C., Parenti, M. D. & Rastelli, G. BEAR, a novel virtual screening methodology for drug discovery. J. Biomol. Screening 16, 129\u2013133 (2011).","journal-title":"J. Biomol. Screening"},{"key":"67283_CR50","doi-asserted-by":"publisher","first-page":"25641","DOI":"10.1074\/jbc.M116.757310","volume":"291","author":"L Dong","year":"2016","unstructured":"Dong, L., Yuan, C., Orlando, B. J., Malkowski, M. G. & Smith, W. L. Fatty Acid Binding to the Allosteric Subunit of Cyclooxygenase-2 Relieves a Tonic Inhibition of the Catalytic Subunit. J. Biol. Chem. 291, 25641\u201325655, https:\/\/doi.org\/10.1074\/jbc.M116.757310 (2016).","journal-title":"J. Biol. Chem."},{"key":"67283_CR51","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1016\/j.bmcl.2017.06.075","volume":"27","author":"Z Zhou","year":"2017","unstructured":"Zhou, Z. et al. Selective inhibitors of human mPGES-1 from structure-based computational screening. Bioorg. Med. Chem. Lett. 27, 3739\u20133743, https:\/\/doi.org\/10.1016\/j.bmcl.2017.06.075 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"67283_CR52","doi-asserted-by":"publisher","first-page":"5605","DOI":"10.1021\/jp100668y","volume":"114","author":"A Hamza","year":"2010","unstructured":"Hamza, A. et al. Understanding microscopic binding of human microsomal prostaglandin E synthase-1 (mPGES-1) trimer with substrate PGH2 and cofactor GSH: insights from computational alanine scanning and site-directed mutagenesis. J. Phys. Chem. B. 114, 5605\u20135616 (2010).","journal-title":"J. Phys. Chem. B."},{"key":"67283_CR53","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1016\/j.bmc.2006.01.010","volume":"14","author":"XQ Huang","year":"2006","unstructured":"Huang, X. Q. et al. Structural and functional characterization of human microsomal prostaglandin E synthase-1 by computational modeling and site-directed mutagenesis. Bioorg. Med. Chem. 14, 3553\u20133562 (2006).","journal-title":"Bioorg. Med. Chem."},{"key":"67283_CR54","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1016\/j.bmc.2011.08.040","volume":"19","author":"A Hamza","year":"2011","unstructured":"Hamza, A., Zhao, X., Tong, M., Tai, H. H. & Zhan, C. G. Novel human mPGES-1 inhibitors identified through structure-based virtual screening. Bioorg. Med. Chem. 19, 6077\u20136086, https:\/\/doi.org\/10.1016\/j.bmc.2011.08.040 (2011).","journal-title":"Bioorg. Med. Chem."},{"key":"67283_CR55","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/path.1711340205","volume":"134","author":"JC Edwards","year":"1981","unstructured":"Edwards, J. C., Sedgwick, A. D. & Willoughby, D. A. The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J. Pathology 134, 147\u2013156 (1981).","journal-title":"J. Pathology"},{"key":"67283_CR56","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10928-012-9295-8","volume":"40","author":"SF Hudachek","year":"2013","unstructured":"Hudachek, S. F. & Gustafson, D. L. Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans. J. Pharmacokinet. Pharmacodyn. 40, 157\u2013176, https:\/\/doi.org\/10.1007\/s10928-012-9295-8 (2013).","journal-title":"J. Pharmacokinet. Pharmacodyn."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67283-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67283-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67283-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T06:16:04Z","timestamp":1723097764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67283-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["67283"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-67283-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"assertion":[{"value":"21 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10187"}}